SLC5A2 and hydrops fetalis: Similarly, a sub-analysis of the FIGARO-DKD trial revealed a notable reduction in the risk of new-onset HF, and an exploratory analysis suggested that this reduction may have been more pronounced in patients who were also taking SGLT-2 inhibitors.